All In Biotech

Drug Trial Radar · NCT05392192

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Chronic Cough

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

Apr 7, 2022

Primary completion

Apr 13, 2023

Study completion Apr 13, 2023

Sponsor

Lead sponsor
Aldeyra Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough

Conditions

  • Chronic Cough

Interventions

  • ADX-629Drug

    Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.

  • PlaceboDrug

    Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was Day 1 - Day 14 for each treatment period.

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Allergy Associates Medical Group, Inc.

    San Diego, California

  • Allergy & Asthma Associates of Santa Clara Valley Research Center

    San Jose, California

  • Cano Research - Hollywood

    Hollywood, Florida

  • Advanced Pulmonary Research Institute

    Loxahatchee Groves, Florida

  • Florida Pulmonary Research Institute LLC

    Winter Park, Florida

  • ClinCept

    Columbus, Georgia

  • Mayo Clinic Pulmonary Clinic Research Unit

    Rochester, Minnesota

  • Mount Sinai

    New York, New York

  • Charlotte Lung & Health/American Health Research

    Charlotte, North Carolina

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio

  • Vital Prospects Clinical Research

    Tulsa, Oklahoma

  • Northwest Research Center

    Portland, Oregon

  • Clinical Research of Rock Hill

    Rock Hill, South Carolina

  • Pharmaceutical Research and Consulting Inc.

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.